- Home
- HCKT vs KALV Comparison
HCKT vs KALV Comparison
Compare HCKT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- KALV
- Stock Information
- Founded
- HCKT 1991
- KALV N/A
- Country
- HCKT United States
- KALV United States
- Employees
- HCKT N/A
- KALV N/A
- Industry
- HCKT Professional Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- KALV Health Care
- Exchange
- HCKT Nasdaq
- KALV Nasdaq
- Market Cap
- HCKT 636.1M
- KALV 637.9M
- IPO Year
- HCKT 1998
- KALV N/A
- Fundamental
- Price
- HCKT $21.09
- KALV $13.41
- Analyst Decision
- HCKT Strong Buy
- KALV Strong Buy
- Analyst Count
- HCKT 3
- KALV 9
- Target Price
- HCKT $29.67
- KALV $26.29
- AVG Volume (30 Days)
- HCKT 361.4K
- KALV 775.3K
- Earning Date
- HCKT 08-05-2025
- KALV 09-04-2025
- Dividend Yield
- HCKT 2.32%
- KALV N/A
- EPS Growth
- HCKT N/A
- KALV N/A
- EPS
- HCKT 0.59
- KALV N/A
- Revenue
- HCKT $309,265,000.00
- KALV N/A
- Revenue This Year
- HCKT $6.06
- KALV N/A
- Revenue Next Year
- HCKT $5.46
- KALV $221.95
- P/E Ratio
- HCKT $35.01
- KALV N/A
- Revenue Growth
- HCKT 3.98
- KALV N/A
- 52 Week Low
- HCKT $19.39
- KALV $7.30
- 52 Week High
- HCKT $34.02
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- HCKT 42.97
- KALV 51.45
- Support Level
- HCKT $19.93
- KALV $12.30
- Resistance Level
- HCKT $20.82
- KALV $13.52
- Average True Range (ATR)
- HCKT 0.72
- KALV 0.56
- MACD
- HCKT 0.03
- KALV 0.04
- Stochastic Oscillator
- HCKT 43.70
- KALV 91.11
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.